Human Immunodeficiency Virus Infection Clinical Trial
Official title:
Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
Potent HIV suppression with Darunavir-based antiretroviral therapy (ART) will lead to repopulation of gastrointestinal-associated lymphoid tissue (GALT) cluster of differentiation (CD)4+ T-cell populations, normalization of systemic immune activation, and improved HIV-associated cardiovascular disease (CVD) risk.
Rationale Infection with HIV causes significant morbidity and mortality, even among individuals who are virologically suppressed with combination anti-retroviral therapy (ART). ART is effective in prolonging life and enabling individuals who are HIV positive to live near-normal life spans. However, these individuals are increasingly developing a number of chronic diseases of aging, such as atherosclerotic cardiovascular disease (ASCVD). The proposed studies will examine the role of highly active antiretroviral therapy in restoring the mucosal immunity and the systemic effect on immune activation, bacterial translocation, and change in HIV-associated cardiovascular disease risk. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05981807 -
HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population
|
||
Completed |
NCT01490359 -
Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men
|
N/A | |
Completed |
NCT03143205 -
Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men
|
N/A | |
Completed |
NCT02738138 -
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
|
Phase 3 | |
Completed |
NCT01791465 -
Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults
|
Phase 4 | |
Completed |
NCT01662336 -
Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program
|
N/A | |
Completed |
NCT01383005 -
Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)
|
N/A | |
Completed |
NCT01328158 -
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
|
N/A | |
Completed |
NCT00711009 -
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
|
Phase 3 | |
Completed |
NCT02817451 -
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants
|
Phase 3 | |
Completed |
NCT02214173 -
The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV
|
N/A | |
Completed |
NCT03284645 -
Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids
|
||
Terminated |
NCT01737359 -
A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.
|
Phase 2 | |
Active, not recruiting |
NCT05141422 -
A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers
|
Phase 1 | |
Completed |
NCT01939197 -
A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection
|
Phase 2/Phase 3 | |
Completed |
NCT01447680 -
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
|
N/A | |
Not yet recruiting |
NCT05769413 -
Awareness of Osteoporosis in HIV Patients
|
||
Withdrawn |
NCT01738555 -
A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects
|
Phase 2 |